Emerging research suggest this peptide, a dual activator targeting both incretin and GIP , may represent a significant advancement for body management . Initial patient investigations have demonstrated substantial reductions in abdominal fat , conceivably outperforming other weight-loss treatments. However , further study is needed to completely as